Hereditary Spherocytosis

Hereditary Spherocytosis (HS) is a genetically determined disorder of the red blood cell (RBC) membrane characterized by the presence of spherical-shaped erythrocytes (spherocytes). These cells are functionally deficient and exhibit osmotic fragility, leading to premature destruction in the spleen (extravascular hemolysis). It is the most common cause of inherited hemolysis in individuals of Northern European descent. Clinical manifestations vary widely, ranging from asymptomatic states to severe life-threatening anemia, jaundice, and splenomegaly.

HS is caused by mutations in genes encoding proteins involved in the vertical linkages between the RBC membrane skeleton and the lipid bilayer. The primary genes involved include:

• ANK1 (Ankyrin-1): Responsible for approximately 50% of cases.


• SPTB (Spectrin beta): Common in autosomal dominant forms.


• SLC4A1 (Band 3 protein): Common in various populations.


• EPB42 (Protein 4.2): Often associated with autosomal recessive forms.


• SPTA1 (Spectrin alpha): Usually associated with severe recessive forms. Transmission is autosomal dominant in roughly 75% of cases; the remainder are autosomal recessive or result from de novo mutations.

The molecular defect leads to a deficiency or dysfunction of membrane proteins (ankyrin, spectrin, or band 3). This disrupts the vertical stabilization of the lipid bilayer, causing the RBC to lose small portions of its membrane (microvesiculation) as it passes through the microvasculature. As the surface-area-to-volume ratio decreases, the cell transforms from a biconcave disc into a sphere. These spherocytes are rigid and lack the deformability required to navigate the narrow fenestrations of the splenic cords. Consequently, they are trapped and destroyed by splenic macrophages, resulting in chronic extravascular hemolysis.

• Prevalence: Approximately 1 in 2,000 to 1 in 5,000 individuals of Northern European ancestry. It is found in all ethnic groups but is less frequently diagnosed in other populations.
• Age: Can be diagnosed at any age, from the neonatal period to late adulthood, depending on severity.
• Gender: Affects males and females equally.

• Family History: A positive history of anemia, jaundice, or early gallbladder removal in a first-degree relative.
• Ancestry: Higher incidence in individuals of Northern European descent.
• Infections: Viral infections (especially Parvovirus B19) can trigger acute hematological crises in predisposed individuals.

A. Early Symptoms

• Mild neonatal jaundice.


• Slightly reduced activity levels. B. Common Symptoms


• Intermittent jaundice (yellowing of skin/eyes).


• Fatigue and exercise intolerance.


• Pallor.


• Dark urine (urobilinogen). C. Advanced Symptoms


• Upper left quadrant abdominal pain (due to splenomegaly).


• Right upper quadrant pain (due to gallstones).


• Iron overload symptoms (in severe cases requiring chronic transfusions). D. Emergency Symptoms


• Aplastic Crisis: Extreme lethargy, fainting, and severe pallor following a viral illness.


• Hemolytic Crisis: Sudden worsening of jaundice, abdominal pain, and fever.

• Vital Signs: Tachycardia may be present if anemia is severe.
• Inspection: Scleral icterus (jaundice) and cutaneous pallor.
• Palpation: Splenomegaly is found in up to 75-90% of symptomatic patients. Hepatomegaly may occur but is less common.
• Auscultation: A flow murmur may be heard over the precordium in cases of significant anemia.

A. Clinical Assessment: Evaluation of family history and physical signs of hemolysis.
B. Laboratory Testing: Initial CBC and peripheral blood smear.
C. Imaging Studies: Ultrasound to detect gallstones or assess spleen size.
D. Functional Tests: Osmotic fragility and EMA binding.
E. Biopsy Findings: Generally not required; bone marrow would show erythroid hyperplasia.
F. Genetic Testing: Next-generation sequencing (NGS) panels for RBC membrane proteins (used for atypical cases).
G. Differential Diagnosis: Autoimmune hemolytic anemia, hereditary elliptocytosis, and G6PD deficiency.

Complete Blood Count (CBC)
Type: Blood Test
Purpose: To assess hemoglobin levels and RBC indices.
Expected Findings: Low to normal Hemoglobin; elevated MCHC (>36 g/dL); increased RDW.
Interpretation: Elevated MCHC is a hallmark of spherocytosis due to relative cellular dehydration. Peripheral Blood Smear
Type: Microscopic Exam
Purpose: Visual identification of cell morphology.
Expected Findings: Presence of small, hyperchromic spherocytes lacking central pallor.
Interpretation: Supports diagnosis but must be differentiated from autoimmune hemolysis. Eosin-5-Maleimide (EMA) Binding Test
Type: Flow Cytometry
Purpose: To quantify the amount of intact membrane proteins.
Expected Findings: Decreased fluorescence.
Interpretation: Currently the gold standard due to high sensitivity and specificity. Osmotic Fragility Test
Type: Blood Test (Functional)
Purpose: To measure RBC lysis in hypotonic saline.
Expected Findings: Increased fragility (cells burst at higher salt concentrations).
Interpretation: Classic test, though less specific than EMA binding.

Abdominal Ultrasound: Purpose: To detect cholelithiasis (gallstones) and measure splenic dimensions.

• Findings: Cholecystolithiasis is common even in childhood.


• Clinical Importance: Guides the need for cholecystectomy during splenectomy.

• Autoimmune Hemolytic Anemia (AIHA): Distinguished by a positive Direct Antiglobulin Test (Coombs test); HS is Coombs-negative.
• ABO Incompatibility (Neonates): Distinguished by blood typing and maternal antibody screening.
• Hereditary Pyropoikilocytosis: Characterized by more extreme red cell fragmentation and thermal sensitivity.
• G6PD Deficiency: Characterized by Heinz bodies and bite cells during oxidative stress.

• Cholelithiasis: Pigment gallstones (bilirubin stones) are the most common complication.
• Aplastic Crisis: Sudden cessation of RBC production, usually due to Parvovirus B

• Hemolytic Crisis: Accelerated RBC destruction during viral infections.
• Post-splenectomy Sepsis: Life-threatening infection by encapsulated bacteria.

A. Lifestyle Modifications: Avoidance of contact sports if splenomegaly is massive (to prevent rupture).
B. Preventive Measures: Folic acid supplementation (1 mg/day) to support increased erythropoiesis.
C. Medical Treatment: * Erythropoietin: Sometimes used in infants to reduce transfusion needs.

• Vaccinations: Essential (Pneumococcal, Meningococcal, H. influenzae) if splenectomy is planned.

• Cholecystectomy: Recommended if symptomatic gallstones are present.

Most patients have a normal life expectancy. Mild cases may never require treatment. Moderate to severe cases require monitoring but respond excellently to splenectomy, which typically normalizes red cell lifespan (though spherocytes will still be visible on the smear).

• Primary: Genetic counseling for affected families.
• Secondary: Regular ultrasound monitoring for gallstones and early vaccination for those requiring surgery.

The following homeopathic remedies have been historically indicated for symptoms associated with Hereditary Spherocytosis. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Hereditary Spherocytosis.